| Drug Name |
Mitoxantrone hydrochloride |
| Drug ID |
BADD_D01481 |
| Description |
An anthracenedione-derived antineoplastic agent. |
| Indications and Usage |
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
L01DB07 |
| DrugBank ID |
DB01204
|
| KEGG ID |
D02166
|
| MeSH ID |
D008942
|
| PubChem ID |
51082
|
| TTD Drug ID |
D0R3JB
|
| NDC Product Code |
63323-132; 58598-0005 |
| Synonyms |
Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone |
